for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

Matters To Be Discussed: Agenda items include presentations from the National Institute for Occupational Safety and Health (NIOSH) and the Agency for Toxic Substances and Disease Registry (ATSDR) regarding the progress of current studies. There will also be a presentation of results from research on cancer mortality among Fernald site workers due to radiation and chemical exposure.

Agenda items are subject to change as priorities dictate.

Contact Persons for More Information: Dr. David Pedersen, Health-Related Energy Research Branch, Division of Surveillance, Hazard Evaluations and Field Studies, NIOSH, CDC, Robert A. Taft Laboratory, 4676 Columbia Parkway, M/S R–44, Cincinnati, Ohio 45226. Telephone 513/841–4400, Fax 513/841–4470.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: November 8, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99–29818 Filed 11–15–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, National Center for Infectious Diseases: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Board of Scientific Counselors, National Center for Infectious Diseases (NCID).

Times and Dates: 9 a.m.–5:30 p.m., December 2, 1999. 8:30 a.m.–2:30 p.m., December 3, 1999.

Place: CDC, Auditorium B, 1600 Clifton Road, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The Board of Scientific Counselors, NCID, provides advice and guidance to the Director, CDC, and Director, NCID, in the following areas: program goals and objectives; strategies; program organization and resources for infectious disease prevention and control; and program priorities.

Matters to be Discussed: Agenda items will include:

1. NCID Update
2. Informatics
3. Chronic Fatigue Syndrome
4. NCID Research Agenda
5. Discussions
6. Vaccine Issues:
   Rotavirus
   Yellow Fever
7. Antimicrobial Resistance
8. Emergency Preparedness—Update
9. Outbreak Investigations—Update
   Nipah virus
   West Nile virus
10. Discussions and Recommendations

Other agenda items include announcements/introductions; follow-up on actions recommended by the Board May 1999; consideration of future directions, goals, and recommendations.

Agenda items are subject to change as priorities dictate.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

Contact Person for More Information: Diane S. Holley, Office of the Director, NCID, CDC, M/S C–20, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone 404/639–0078.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: November 8, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99–29819 Filed 11–15–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99D–4487]

Medical Devices; Draft Guidance for Conducting Stability Testing to Support an Expiration Date Labeling Claim for Medical Gloves; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ''Guidance for Conducting Stability Testing to Support an Expiration Date Labeling Claim for Medical Gloves.'' This guidance is neither final nor is it in effect at this time. This guidance describes the information needed to support an expiration date labeling claim for powdered or powder-free, surgeon's or patient examination gloves. Expiration dating of medical gloves is voluntary at this time. FDA recommends that manufacturers, repackagers, or importers who add an expiration date labeling claim follow the enclosed recommended criteria and protocols for conducting testing described in this guidance.

DATES: Written comments concerning this draft guidance must be received by February 14, 2000.

ADDRESSES: See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the draft guidance. Submit written requests for single copies on a 3.5″ diskette of the guidance document entitled, ''Guidance for Conducting Stability Testing to Support an Expiration Date Labeling Claim for Medical Gloves'' to the Division of Small Manufacturers Assistance (HFZ–220), Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two self-addressed adhesive labels to assist that office in processing your request, or fax your request to 301–443–8818. Written comments concerning this guidance must be submitted to the Dockets Management Branch, (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Chiu S. Lin, Center for Devices and Radiological Health (HFZ–480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–8913.

SUPPLEMENTARY INFORMATION:

I. Background

It is estimated that millions of health care workers use medical gloves on a daily basis as a barrier against blood borne pathogens and microorganisms. The effective use of medical gloves as a barrier, however, is dependent upon the integrity of the glove material. Degradation of the glove material may occur when exposed to various types of manufacturing processes (e.g., chlorination) and/or environmental conditions.

In response to growing concerns regarding the use of natural rubber latex (NRL), the National Institute of Occupational Safety and Health recently issued a safety alert recommending the use of powder-free medical gloves as a means to reduce exposure to natural

rubber latex allergens through the medical glove powder. With the present shift in the medical glove market from powdered medical gloves to powder-free, the potential for a rapid increase in the demand for powder-free or nonpowdered gloves could result in products with poor barrier integrity and/or unacceptable shelf-life. Processes to remove glove powder such as chlorination have an adverse effect on various mechanical and physical glove properties, which may affect shelf-life.

Expiration dating is not currently required for patient examination or surgeon's gloves. However, FDA has just published a proposed regulation to require expiration dating for all medical gloves (64 FR 41709, July 30, 1999). Currently, if manufacturers voluntarily label their glove with an expiration date, they are expected to have real-time data to support the shelf-life labeling claim. If real-time data are not available, then a provisional shelf-life labeling claim, not to exceed a period of 2 years, may be established based on accelerated aging test data. This guidance provides recommended test methodology and protocols for both real-time and accelerated aging that the manufacturers may utilize to support an expiration date labeling claim. Additionally, manufacturers of medical gloves may utilize this guidance document to design process controls, as described in the quality system regulation, for controlling manufacturing processes, such as chlorination, to minimize adverse effects on glove barrier properties.

II. Significance of Guidance

This guidance document represents the agency's current thinking on conducting stability testing to support an expiration date labeling claim for medical gloves. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the applicable statute, regulations, or both.

The agency has adopted good guidance practices (GGP's), which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents (62 FR 8961, February 27, 1997). This guidance document is issued as a Level 1 guidance consistent with GGP's.

III. Electronic Access

In order to receive the ''Guidance for Conducting Stability Testing to Support an Expiration Date Labeling Claim for Medical Gloves'' via your fax machine, call the CDRH Facts-On-Demand (FOD) system at 800–899–0381 or 301–827–0111 from a touch-tone telephone. At the first voice prompt press 1 to access DSMA Facts, at second voice prompt press 2, and then enter the document number (1355) followed by the pound sign (#). Then follow the remaining voice prompts to complete your request.

Persons interested in obtaining a copy of the guidance may also do so using the Internet. The Center for Devices and Radiological Health (CDRH) maintains an entry on the Internet for easy access to information including text, graphics, and files that may be downloaded to a personal computer with access to the Internet. Updated on a regular basis, the CDRH home page includes ''Guidance for Conducting Stability Testing to Support an Expiration Date Labeling Claim for Medical Gloves,'' device safety alerts, **Federal Register** reprints, information on premarket submissions (including lists of approved applications and manufacturers' addresses), small manufacturers' assistance, information on video conferencing and electronic submissions, mammography matters, and other device-oriented information. The CDRH home page may be accessed at http://www.fda.gov/cdrh. ''Guidance for Conducting Stability Testing to Support an Expiration Date Labeling Claim for Medical Gloves'' will be available at http://www.fda.gov/cdrh.

IV. Comments

Interested persons may, on or before February 14, 2000, submit to the Dockets Management Branch (address above) written comments regarding this draft guidance. Such comments will be considered when determining whether to amend the current guidance. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance document and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: October 28, 1999.

Linda S. Kahan,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 99–29791 Filed 11–15–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–0486]

Physician and Patient Labeling for Progestational Drug Products; Warnings and Contraindications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is revoking its previously issued guidance texts for physician and patient labeling for progestational drug products that were published in the **Federal Register** of January 12, 1989 (54 FR 1243). A notice announcing FDA's intention to revoke these guidance texts was published in the **Federal Register** on April 13, 1999 (64 FR 18035). FDA received no comments on this notice. The guidance texts, which supplied physician and patient labeling for progestational drug products as a class, are no longer needed for the reasons discussed in the proposed rule on progestational drug products published in the **Federal Register** on April 13, 1999 (64 FR 17985). For additional information, see the final rule on progestational drug products that appears elsewhere in this issue of the **Federal Register**.

EFFECTIVE DATE: November 16, 2000.

FOR FURTHER INFORMATION CONTACT: Diane V. Moore, Center for Drug Evaluation and Research (HFD–580), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4260.

Dated: November 4, 1999.

Margaret M. Dotzel,

Acting Associate Commissioner for Policy.

[FR Doc. 99–29855 Filed 11–15–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute of Health

National Cancer Institute; Notice of Closed meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,